{"id":"NCT03283085","sponsor":"Shire","briefTitle":"A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)","officialTitle":"A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-27","primaryCompletion":"2023-12-13","completion":"2023-12-13","firstPosted":"2017-09-14","resultsPosted":"2024-06-21","lastUpdate":"2024-06-21"},"enrollment":557,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease","Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"25 mg Ontamalimab","otherNames":["PF-00547659","SHP647"]},{"type":"DRUG","name":"75 mg Ontamalimab","otherNames":["SHP647","PF-00547659"]}],"arms":[{"label":"Ulcerative Colitis (UC): Ontamalimab 25 mg","type":"EXPERIMENTAL"},{"label":"UC: Ontamalimab 25mg then 75 mg","type":"EXPERIMENTAL"},{"label":"UC: Ontamalimab 75 mg","type":"EXPERIMENTAL"},{"label":"Crohn's disease (CD): Ontamalimab 25 mg","type":"EXPERIMENTAL"},{"label":"CD: Ontamalimab 25mg then 75 mg","type":"EXPERIMENTAL"},{"label":"CD: Ontamalimab 75 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and tolerability of long-term treatment with ontamalimab in participants with moderate to severe Ulcerative Colitis (UC) or Crohn's disease (CD)","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","timeFrame":"From first dose of study drug up to end of study [EOS] (up to 5.79 years)","effectByArm":[{"arm":"UC: Ontamalimab 25 mg","deltaMin":67,"sd":null},{"arm":"UC: Ontamalimab 25 mg Then 75 mg","deltaMin":122,"sd":null},{"arm":"UC: Ontamalimab 75 mg","deltaMin":203,"sd":null},{"arm":"CD: Ontamalimab 25 mg","deltaMin":4,"sd":null},{"arm":"CD: Ontamalimab 25 mg Then 75 mg","deltaMin":8,"sd":null},{"arm":"CD: Ontamalimab 75 mg","deltaMin":17,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":17},"locations":{"siteCount":419,"countries":["United States","Argentina","Australia","Austria","Belgium","Bosnia and Herzegovina","Bulgaria","Canada","Colombia","Croatia","Czechia","Estonia","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Lebanon","Lithuania","Mexico","Netherlands","New Zealand","Poland","Portugal","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Spain","Switzerland","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b5fe14db2bf003ab476b8"]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":89},"commonTop":["Corona virus infection","Colitis ulcerative","Nasopharyngitis","Anaemia","Headache"]}}